Skip to main content
Erschienen in: Uro-News 5/2019

29.04.2019 | Harnblasenkarzinom | Zertifizierte Fortbildung

Der aktuelle Empfehlungsstand

Instillationstherapie beim nicht muskelinvasiven Harnblasenkarzinom

verfasst von: PD Dr. med. Frank Christoph, Tabea Koch, Simon Blaschke, Frank König, Stefan Lebentrau, Johann Wendler, Martin Schostak

Erschienen in: Uro-News | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Einteilung oberflächlicher Urothelkarzinome in Niedrig-, Mittel- und Hochrisikokarzinome hat sich als Grundlage der Therapieentscheidung etabliert. Dabei gilt, ein ideales Gleichgewicht zwischen Risikoreduktion und Nebenwirkungsmuster zu finden: So ist eine adjuvante Instillation nicht immer empfohlen — und wenn, gilt es auch hier, die richtige Variante zu wählen.
Literatur
1.
Zurück zum Zitat Verbreitung von Krebserkrankungen in Deutschland, Entwicklungen der Prävalenzen in Deutschland zwischen 1990 und 2010, Robert-Koch-Institut, www.krebsdaten.de Verbreitung von Krebserkrankungen in Deutschland, Entwicklungen der Prävalenzen in Deutschland zwischen 1990 und 2010, Robert-Koch-Institut, www.​krebsdaten.​de
2.
Zurück zum Zitat Grotenhuis A et al. The effect of smoking and timing of smoking cessation on clinical outcome in non-muscle-invasive bladder cancer. Urol Oncol. 2015; http://doi.org/f258zj Grotenhuis A et al. The effect of smoking and timing of smoking cessation on clinical outcome in non-muscle-invasive bladder cancer. Urol Oncol. 2015; http://​doi.​org/​f258zj
3.
Zurück zum Zitat Shang P et al. Intravesical bacillus Calmette-Guerin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst Rev. 2011; http://doi.org/brb8vn Shang P et al. Intravesical bacillus Calmette-Guerin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst Rev. 2011; http://​doi.​org/​brb8vn
4.
Zurück zum Zitat Huncharek M et al. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res. 2001; 21: 765–976PubMed Huncharek M et al. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res. 2001; 21: 765–976PubMed
5.
Zurück zum Zitat Malmstrom P et al. An individual patient data-analysis of the long-term outcome of randomized studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle invasive bladder cancer. Eur Urol. 2009; 56: 247–56CrossRefPubMed Malmstrom P et al. An individual patient data-analysis of the long-term outcome of randomized studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle invasive bladder cancer. Eur Urol. 2009; 56: 247–56CrossRefPubMed
6.
Zurück zum Zitat Bohle A et al. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003; 169: 90–5CrossRefPubMed Bohle A et al. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003; 169: 90–5CrossRefPubMed
7.
Zurück zum Zitat Sylvester R et al. Intravesical bacillus Calmette-Guerrin reduces the risk of progression in patients with superficial bladder cancer: a meta analysis of the published results of the randomized clinical trials. J Urol. 2002; 168: 1964–70CrossRefPubMed Sylvester R et al. Intravesical bacillus Calmette-Guerrin reduces the risk of progression in patients with superficial bladder cancer: a meta analysis of the published results of the randomized clinical trials. J Urol. 2002; 168: 1964–70CrossRefPubMed
8.
Zurück zum Zitat Gardmark T et al. Analysis of clinical characteristics, management and survival of patients with Ta T1 bladder tumours in Sweden between 1997 and 2001. Scand J Urol Nephrol. 2006; 40: 276–82CrossRefPubMed Gardmark T et al. Analysis of clinical characteristics, management and survival of patients with Ta T1 bladder tumours in Sweden between 1997 and 2001. Scand J Urol Nephrol. 2006; 40: 276–82CrossRefPubMed
9.
Zurück zum Zitat Huncharek M et al. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metanalytic comparison of chemotherapy versus bacilli Calmette Guerin immunotherapy. Am J Clin Oncol. 2004; 27: 522–8CrossRefPubMed Huncharek M et al. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metanalytic comparison of chemotherapy versus bacilli Calmette Guerin immunotherapy. Am J Clin Oncol. 2004; 27: 522–8CrossRefPubMed
10.
Zurück zum Zitat Sylvester R et al. Long term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerrin plus isoniazid in patients with intermediate- and high risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010; 57: 766–73CrossRefPubMed Sylvester R et al. Long term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerrin plus isoniazid in patients with intermediate- and high risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010; 57: 766–73CrossRefPubMed
11.
Zurück zum Zitat Witjes A et al. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of Bacillus Calmette-Guerin (BCG): results of an international individual patient data survey (IPDS). BJU Int. 2013; 112: 742–50CrossRefPubMedPubMedCentral Witjes A et al. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of Bacillus Calmette-Guerin (BCG): results of an international individual patient data survey (IPDS). BJU Int. 2013; 112: 742–50CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Brausi M et al. Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary group randomized phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014; 65: 69–76CrossRefPubMed Brausi M et al. Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary group randomized phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014; 65: 69–76CrossRefPubMed
13.
Zurück zum Zitat Oddens J et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013; 63: 262–72CrossRef Oddens J et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013; 63: 262–72CrossRef
14.
Zurück zum Zitat Martinez-Pineiro L et al. Maintenance therapy with 3-monthly bacillus Calmette-Guerin for 3 years is not superior to standard induction therapy in high-risk non-muscle-invasive urothelial bladder carcinoma: final results of randomized CUETO study 98013. Eur Urol. 2015; 68; 256–62CrossRefPubMed Martinez-Pineiro L et al. Maintenance therapy with 3-monthly bacillus Calmette-Guerin for 3 years is not superior to standard induction therapy in high-risk non-muscle-invasive urothelial bladder carcinoma: final results of randomized CUETO study 98013. Eur Urol. 2015; 68; 256–62CrossRefPubMed
15.
Zurück zum Zitat Lamm D et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000; 163; 1124–9CrossRefPubMed Lamm D et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000; 163; 1124–9CrossRefPubMed
16.
Zurück zum Zitat Yuk H et al. Should intravesical Bacillus Calmette-Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle.invasive bladder cancer? PLoS One. 2018; http://doi.org/gfqt3f Yuk H et al. Should intravesical Bacillus Calmette-Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle.invasive bladder cancer? PLoS One. 2018; http://​doi.​org/​gfqt3f
17.
Zurück zum Zitat Kamat A et al. Myths and mysteries surrounding bacillus Calmette-Guerin therapy for bladder cancer. Eur Urol. 2014; 65: 267–9CrossRefPubMed Kamat A et al. Myths and mysteries surrounding bacillus Calmette-Guerin therapy for bladder cancer. Eur Urol. 2014; 65: 267–9CrossRefPubMed
18.
Zurück zum Zitat van der Meijden A et al. Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer genito-urinary group phase III trial. Eur Urol. 2003; 44: 429–34CrossRefPubMed van der Meijden A et al. Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer genito-urinary group phase III trial. Eur Urol. 2003; 44: 429–34CrossRefPubMed
19.
Zurück zum Zitat Herr H et al. Intravesical bacillus Calmette-Guerin outcomes in patients with bladder cancer and asymptomatic bacteriura. J Urol. 2012; 187: 435–7CrossRefPubMed Herr H et al. Intravesical bacillus Calmette-Guerin outcomes in patients with bladder cancer and asymptomatic bacteriura. J Urol. 2012; 187: 435–7CrossRefPubMed
20.
Zurück zum Zitat Colombel M et al. The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double blind, placebo controlled, multicenter study. J Urol. 2006; 176: 935–9CrossRefPubMed Colombel M et al. The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double blind, placebo controlled, multicenter study. J Urol. 2006; 176: 935–9CrossRefPubMed
21.
Zurück zum Zitat Au J et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trail. J Natl Cancer Inst. 2001; 93: 597–604CrossRefPubMed Au J et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trail. J Natl Cancer Inst. 2001; 93: 597–604CrossRefPubMed
22.
Zurück zum Zitat Herr HW. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol. 2000; 163: 60–1CrossRefPubMed Herr HW. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol. 2000; 163: 60–1CrossRefPubMed
23.
Zurück zum Zitat Lerner S et al. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol. 2009; 27: 155–9CrossRefPubMed Lerner S et al. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol. 2009; 27: 155–9CrossRefPubMed
24.
Zurück zum Zitat Shariat S et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol. 2007; 51: 137–49CrossRefPubMed Shariat S et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol. 2007; 51: 137–49CrossRefPubMed
25.
Zurück zum Zitat Tilki D et al. Validation of the AJCC TNM substaging of T2 bladder cancer: deep muscle invasioin is associated with significantly worse outcome. Eur Urol. 2010; 58: 112–7CrossRefPubMed Tilki D et al. Validation of the AJCC TNM substaging of T2 bladder cancer: deep muscle invasioin is associated with significantly worse outcome. Eur Urol. 2010; 58: 112–7CrossRefPubMed
26.
Zurück zum Zitat Svatek R et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int. 2011; 107; 898–904CrossRefPubMed Svatek R et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int. 2011; 107; 898–904CrossRefPubMed
27.
Zurück zum Zitat Rigatti P et al. Combined intravesical chemotherapy with mitomycin C and local bladder microwave-induced hyperthermia as a preoperative therapy for superficial bladder tumors. A preliminary clinical study. Eur Urol. 1991; 20}: 204–10CrossRefPubMed Rigatti P et al. Combined intravesical chemotherapy with mitomycin C and local bladder microwave-induced hyperthermia as a preoperative therapy for superficial bladder tumors. A preliminary clinical study. Eur Urol. 1991; 20}: 204–10CrossRefPubMed
28.
Zurück zum Zitat Lammers RJ et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol. 2011; 60: 81–93CrossRefPubMed Lammers RJ et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol. 2011; 60: 81–93CrossRefPubMed
29.
Zurück zum Zitat Sousa A, Pineiro I, Rodriguez S et al. Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate-high-risk non muscle-invasive bladder cancer. Int J Hyperthermia. 2016; 32: 374–80CrossRefPubMed Sousa A, Pineiro I, Rodriguez S et al. Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate-high-risk non muscle-invasive bladder cancer. Int J Hyperthermia. 2016; 32: 374–80CrossRefPubMed
30.
Zurück zum Zitat Arends T et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol. 2016; 69: 1046–52CrossRefPubMed Arends T et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol. 2016; 69: 1046–52CrossRefPubMed
31.
Zurück zum Zitat Ayres B et al. 3-year single centre UK experience of radiofrequency hyperthermia and mitomycin C in BCG failures. BJU Int Suppl. 2010; http://doi.org/b99fh4 Ayres B et al. 3-year single centre UK experience of radiofrequency hyperthermia and mitomycin C in BCG failures. BJU Int Suppl. 2010; http://​doi.​org/​b99fh4
32.
Zurück zum Zitat DeJong J et al. Hyperthermic intravesical chemotherapy for BCG unresponsive non-muscle invasive bladder cancer patients. Bladder Cancer. 2018; 4: 395–401CrossRef DeJong J et al. Hyperthermic intravesical chemotherapy for BCG unresponsive non-muscle invasive bladder cancer patients. Bladder Cancer. 2018; 4: 395–401CrossRef
33.
Zurück zum Zitat Witjes J et al. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J Urol. 2009; 27: 319-24CrossRefPubMedPubMedCentral Witjes J et al. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J Urol. 2009; 27: 319-24CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Martini T et al: Validation of RiskCheck Bladder Cancer ©, version 5.0 for risk-adapted screening of bladder cancer. Urol Int. 2013; 91: 175–81.CrossRefPubMed Martini T et al: Validation of RiskCheck Bladder Cancer ©, version 5.0 for risk-adapted screening of bladder cancer. Urol Int. 2013; 91: 175–81.CrossRefPubMed
Metadaten
Titel
Der aktuelle Empfehlungsstand
Instillationstherapie beim nicht muskelinvasiven Harnblasenkarzinom
verfasst von
PD Dr. med. Frank Christoph
Tabea Koch
Simon Blaschke
Frank König
Stefan Lebentrau
Johann Wendler
Martin Schostak
Publikationsdatum
29.04.2019
Verlag
Springer Medizin
Erschienen in
Uro-News / Ausgabe 5/2019
Print ISSN: 1432-9026
Elektronische ISSN: 2196-5676
DOI
https://doi.org/10.1007/s00092-019-2063-y

Weitere Artikel der Ausgabe 5/2019

Uro-News 5/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.